Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05961839 · ClinicalTrials.gov registry record · Phase 1
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Phase 1 study, sponsored by Schrödinger.
- Terminated
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT05961839 is a Phase 1 study that was terminated before completion, run by Schrödinger. The registered enrollment target is 66 participants.
The verdict
NCT05961839, a Phase 1 study, was terminated before completion, sponsored by Schrödinger.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Interventions
- DRUG SGR-2921
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2025-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05961839
The ClinicalTrials.gov registry entry for NCT05961839 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Schrödinger, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGR-2921 is the first listed.
NCT05961839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05961839 about?
NCT05961839 is a clinical study titled "Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome". The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
What is the current status of trial NCT05961839?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2023-09-27. Estimated completion is 2025-09-09.
What interventions are being tested in trial NCT05961839?
The interventions under investigation include: SGR-2921 (DRUG).
Who is sponsoring clinical trial NCT05961839?
This trial is sponsored by Schrödinger, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.